Lupin net profit rises 49.46 percent to Rs 303 crore for June quarter

Consolidated sales for the quarter under review also rose to Rs 4,355.83 crore as against Rs 3,774.57 crore during the same period a year ago, Lupin stated.

Mumbai: Drug firm, Lupin Ltd on August 7 reported a 49.46 per cent rise in consolidated net profit to Rs 303.05 crore for the quarter ended June 30, 2019, on account of robust sales in India and overseas.

Read Also: Lupin gets EIR from USFDA for Oral Dosage facility in Aurangabad

The company had posted a net profit of Rs 202.76 crore in the year-ago period, Lupin said in a filing to the BSE.

Consolidated sales for the quarter under review also rose to Rs 4,355.83 crore as against Rs 3,774.57 crore during the same period a year ago.

Based in Mumbai, the company's key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis. The company was founded in 1968 by Desh Bandhu Gupta,

who was a professor of chemistry at BITS-Pilani, Rajasthan.

Read Also: Lupin to focus on launch of biosimilar, inhalation product in US this fiscal